Ariemedi Medical Technology Completes Series A+ Financing of Hundreds of Millions of RMB

Recently, Arimedy Medical Technology (Beijing) Co., Ltd. (“Arimedy”) completed a Series A+ financing round amounting to hundreds of millions of yuan, with Hai Rui Investment and Haier Capital jointly leading the investment.

Arimedy, founded in 2016 and headquartered in Haidian District, Beijing, is a national high-tech enterprise specializing in the research, development, manufacturing, and sales of intelligent products for augmented reality-based precision navigation. The company is committed to providing advanced integrated smart solutions for industries such as healthcare, military, industrial, and education.

Arimedy has assembled a team of professionals specializing in optics, electronics, mechanics, and artificial intelligence, boasting a high-caliber workforce proficient in product R&D, quality control, testing and certification, and market development. The company maintains close collaborations with prestigious universities such as Beijing Institute of Technology and Tsinghua University, establishing an integrated collaborative innovation model encompassing industry, academia, and research. With over a decade of experience in the design, R&D, and manufacturing of augmented reality navigation devices, Arimedy has filed more than 100 national invention patents and mastered core technologies including positioning sensing, optoelectronic imaging, virtual simulation, and human-computer interaction. By fostering strong partnerships with numerous leading enterprises in the industry, the company provides customers with world-class application technology services and development platforms. Since its inception, Arimedy has served as the lead organization for key national R&D programs under the 13th and 14th Five-Year Plans, the Beijing AI Health Special Project, and the Ministry of Industry and Information Technology’s 5G + Telemedicine Pilot Special Project. Its products have obtained one Class III and three Class II medical device registration certificates from the National Medical Products Administration. Furthermore, its core tracking and positioning components have broken the monopoly held by imported products in this field. Arimedy has been recognized as a National High-Tech Enterprise, a Beijing “Specialized, Refined, Differential, and Innovative” (SRDI) Enterprise, and a Zhongguancun High-Tech Enterprise.

The funds raised in this round of financing will be primarily allocated to scientific research collaborations and clinical trials, iterative upgrades of products and technologies, and market expansion. This will further consolidate and expand the company’s industry influence in the field of intelligent healthcare, striving to realize the vision of “Precision Navigation, Smartly Guiding the Future.” Committed to independent high-tech innovation, Arimedy will continue to provide reliable, high-quality products and services, leveraging technology to benefit national livelihood and the economy, with the ambition of becoming a leading provider of augmented reality-based precision navigation solutions.

Arimedy has accumulated nearly 20 years of expertise in the field of innovative medical devices, developing solutions that specifically address industry needs and providing customized services and solutions to many leading medical device companies. Specifically, Arimedy has implemented the following three initiatives:

Self-developed core components for optical and electromagnetic tracking and positioning, providing hardware solutions for the industry. These positioning components achieve precise localization based on the principles of optical reflection or electromagnetic attenuation, enabling sub-millimeter high-precision instrument positioning. Previously, domestic surgical navigation robot manufacturers could only procure components from foreign monopolistic enterprises, which has long been a persistent pain point in the industry. Arimedy has broken through numerous key core technologies in optical and electromagnetic components, achieving practical applications of target tracking and positioning across various scenarios and surgical procedures. Currently, the application of these core positioning components is no longer limited to the medical field; they have also been implemented in industrial 3D scanning, motion analysis, and visual sensing.

Modularizing Technologies for Surgical Navigation Robots and Imaging Equipment to Provide Software Solutions for the IndustryThe technology landscape of the surgical navigation robot and imaging equipment industry is highly complex, involving core technologies such as preoperative planning, intraoperative positioning and navigation, integrated software-hardware collaborative control, and image fusion and enhancement. Leveraging its robust technical expertise, Arimedy Medical Technology (Beijing) Co., Ltd. has modularized and standardized these related technologies, establishing a standardized service system to provide modular technical solutions for enterprises across various sub-sectors.

Standardize registration testing and clinical trial capabilities to provide the industry with an integrated solution from R&D to regulatory approval. Innovative active medical devices require long-term accumulation of experience in major development areas such as product selection, electromagnetic compatibility (EMC) testing, and clinical protocol design, posing significant challenges to the business expansion of traditional medical device companies. Arimedy’s self-developed endoscopic skull base surgical navigation system has obtained a National Class III Medical Device Registration Certificate, validating its full-process capabilities in R&D, testing, clinical trials, and regulatory approval. Arimedy opens up its experience and technology to the industry, providing enterprise clients with one-stop services from R&D to regulatory approval, accelerating the development of surgical robots for client companies, and promoting advancements in both the technological and supply sides of the industry.

Since then, Arimedy has moved upstream in the industry, providing support to more outstanding enterprises in the research and development, registration, and certification of surgical navigation robots, imaging equipment image enhancement, simulation, and more, thereby promoting the rapid development of the industry.

Mr. Hao Qun, Founder of Hairui Investment, stated: “Arimedy boasts a robust R&D and technical team, having achieved numerous milestone advancements in technological research, industrial implementation, and corporate financing. Over the past year, the team united to overcome many challenges posed by the pandemic, generating tens of millions in revenue by empowering medical device companies with precise navigation technology. We look forward to seeing the company evolve from a terminal product manufacturer into a solutions provider, carving out its own innovative model in the high-end medical device CDMO sector and leveraging its solid technical capabilities to empower its industry clients.”

Mr. Zhang Jiacheng, Partner at Haier Capital, stated: "The surgical robotics sector is an emerging subfield that has been validated in North America and Europe but remains in its early stages of development in China. Arimedy is firmly rooted in the surgical robotics domain, boasting a robust technical team and extensive experience in industrial commercialization. The company continues to strengthen its technological capabilities in image processing and precision navigation, while empowering peer enterprises to foster mutual growth. As an investor in the company, Haier Capital is delighted to see Arimedy gaining increasing recognition from partners. We are also pleased to collaborate with Arimedy to enhance the technological prowess of China's surgical robotics sector and, in practice, provide patients with more precise and safer clinical surgical services."

Hairyi Investment, established in 2017, is a primary market investment management team focused on the defense industry, new energy vehicles and autonomous driving, semiconductors and electronic equipment, healthcare, and intelligent manufacturing. Hairyi Investment currently manages over twenty funds with total assets under management exceeding RMB 4 billion. Through lead investments, co-investments, and investment advisory services, it has mobilized more than RMB 5 billion in social capital investment, supporting tens of thousands of jobs. The firm has invested in over 50 high-quality enterprises. To date, two portfolio companies have exited via mergers and acquisitions, eight have successfully gone public, and several others are awaiting review by the China Securities Regulatory Commission or stock exchanges. Driven by the company’s support, a large number of these enterprises have grown into industry leaders, fostering and leading the vigorous development of related emerging fields and industrial chains, thereby creating significant economic benefits and social value.

Haier Capital, established in 2010, is an investment platform under Haier Financial Holdings. Positioned as a co-creation platform for full-industry-ecosystem investment, it focuses on industrial investments in the healthcare and intelligent technology sectors. It strategically targets key segments including medical technology, healthcare services, medical devices, biopharmaceuticals, and intelligent manufacturing. By providing not only financial support but also access to industrial and ecosystem resources, Haier Capital facilitates industry restructuring and builds a multi-party win-win ecosystem cluster to empower partners across various sectors. The firm manages over RMB 30 billion in investment assets.